Bristol Myers Squibb has announced significant regulatory milestones that are reshaping the treatment landscape for classical Hodgkin lymphoma (cHL), with new approvals in both the United States and the European Union. These developments position nivolumab (Opdivo®), a PD-1 immune checkpoint inhibitor, at the forefront of immunotherapy-based combinations across multiple stages of the disease.

Landmark Approvals Across Treatment Settings

In the United States, the Food and Drug Administration (FDA) has approved nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients aged 12 years and older with previously untreated Stage III or IV cHL. This marks the first immunotherapy-based combination approved in the frontline setting for advanced disease, representing a paradigm shift from traditional chemotherapy-only regimens.

In parallel, the European Commission has approved nivolumab in combination with brentuximab vedotin for children (≥5 years), adolescents, and young adults (up to 30 years) with relapsed or refractory cHL following one prior line of therapy. This is the first immunotherapy combination approved in this treatment setting in the EU.

Strong Clinical Evidence Driving Approvals

The U.S. approval is supported by findings from the Phase 3 SWOG 1826 trial, which demonstrated a 58% reduction in the risk of disease progression or death مقارنة with standard-of-care therapy. The study also showed a statistically significant improvement in progression-free survival, with early overall survival data indicating fewer deaths in the nivolumab combination arm.

The EU approval is based on the Phase 2 CheckMate -744 study, which reported high complete metabolic response rates in pediatric and young adult patients with relapsed or refractory disease. The regimen enabled most patients to proceed to consolidation therapy while maintaining a manageable safety profile, highlighting the potential for chemotherapy-sparing approaches.

Safety Profile and Considerations

Nivolumab-based regimens are associated with immune-mediated adverse events, including pneumonitis, colitis, hepatitis, endocrinopathies, and dermatologic reactions. In the SWOG 1826 study, serious adverse events occurred in 39% of patients, with the most common including peripheral neuropathy, neutropenia, and pyrexia. Fatal events were rare (0.6%) and primarily related to sepsis. These findings underscore the need for careful patient monitoring and pharmacovigilance.

Implications for Practice in Africa

The introduction of immunotherapy combinations into both frontline and relapsed settings represents a major advancement in cHL management. For African health systems, these developments raise important considerations:

• Access and affordability: High costs of immunotherapy may limit widespread uptake, necessitating strategic procurement and financing mechanisms.

• Health system readiness: Implementation will require strengthening oncology infrastructure, diagnostic capacity (including biomarker testing), and clinician training.

• Treatment outcomes: Improved progression-free survival and durable responses offer the potential to reduce relapse rates and long-term treatment burden.

Conclusion

The expanded approvals of nivolumab-based combinations signal a transformative shift in classical Hodgkin lymphoma treatment, moving toward more effective, immune-based strategies across the disease continuum. While challenges remain in ensuring equitable access, these innovations provide renewed optimism for improving patient outcomes globally, including in resource-limited settings.